A novel Kv7 potassium channel opener, may offer a unique treatment option for patients with resistant focal onset seizures.

A new study published in JAMA Network Open highlights the significant environmental footprint of medical imaging contrast ...

First data reported from non-MTS and bilateral MTLE subjects demonstrate robust seizure reduction - LOW DOSE COHORT: 89% median reduction in disabling seizures for unilateral subjects with MTS at the ...

Brazil's Chamber of Deputies could allow former President Jair Bolsonaro a big reduction in 27-year prison sentence he is ...

This peer-reviewed publication marks an important milestone following initial release of study information in August 2024 (see "Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT"). The ...

Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant ...

Planned early-term birth based on risk stratification for preeclampsia reduced the incidence of the complication at term ...

Screening pregnant women at 36 weeks using a validated risk model and offering risk-stratified planned early-term birth ...

HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful ...

Two Appalachian states are bound by the same opioid crisis but are taking different paths forward. The Post traveled to West ...

London stocks nudged higher in early trade on Monday as investors eyed this week’s policy announcement from the US Federal ...

Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation December 10, 2025 ...